Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC11396 structure
    GC11396SNS-032 (BMS-387032)
    CAS: 345627-80-7
    纯度: >99.00%

    A Cdk2, Cdk7, and Cdk9 inhibitor

  • GC11418 structure
    GC11418MI-2
    CAS: 1271738-62-5
    纯度: >99.00%

    An inhibitor of menin-MLL fusion protein interactions

  • GC11439 structure
    GC11439MG 149
    CAS: 1243583-85-8
    纯度: >99.50% / >98.00%

    MG 149是一种组蛋白乙酰转移酶(HAT)抑制剂,对Tip60和MOF的IC 50 值分别为74μM和47μM。

  • GC11445 structure
    GC11445YH239-EE
    CAS: 1364488-67-4
    纯度: >99.50%

    A prodrug form of YH 239

  • GC11455 structure
    GC11455Silvestrol
    CAS: 697235-38-4
    纯度: >98.00%

    Silvestrol 是一种真核翻译起始因子 4A (eIF4A) 抑制剂,从 Agave americana Linn 中分离出来。Silvestrol 诱导自噬和半胱天冬酶介导的细胞凋亡。

  • GC11459 structure
    GC11459Xanthurenic acid
    CAS: 59-00-7
    纯度: >99.50% / >98.00%

    Xanthurenic acid是一种内源性II组代谢型谷氨酸受体激动剂,参与丘脑的感觉传递。

  • GC11469 structure
    GC11469TASIN-1
    CAS: 792927-06-1

    An inhibitor of truncated APC

  • GC11482 structure
    GC11482Thapsigargin
    CAS: 67526-95-8
    纯度: >98.00% / >99.50%

    他普西加林是一种肌浆网/内质网Ca2+ ATP酶泵的抑制剂。

  • GC11488 structure
    GC11488TCS JNK 5a
    CAS: 312917-14-9
    纯度: >98.00%

    A selective inhibitor of JNK2 and JNK3

  • GC11496 structure
    GC11496TLQP 21
    CAS: 869988-94-3

    TLQP 21 是一种 VGF 衍生肽,具有内分泌和内分泌特性,是一种有效的 G 蛋白偶联受体补体 3a 受体 1 (C3aR1) 激动剂(EC50:小鼠 TLQP 21\u003d10.3 μM;人 TLQP 21\u003d68.8 μM) .

  • GC11499 structure
    GC11499Enzastaurin (LY317615)
    CAS: 170364-57-5
    纯度: >99.50%

    Enzastaurin (LY317615)是一种ATP竞争性、选择性的PKCβ抑制剂,IC 50 值为6nM。

  • GC11511 structure
    GC11511Vincristine sulfate
    CAS: 2068-78-2
    纯度: >99.50%

    An antimitotic inhibitor of tubulin polymerization

  • GC11528 structure
    GC11528Orotic acid
    CAS: 65-86-1
    纯度: >98.00%

    乳清酸 (6-Carboxyuracil) 是嘧啶核苷酸和 RNA 生物合成的前体,从线粒体二氢乳清酸脱氢酶 (DHODH) 中释放出来,通过细胞质 UMP 合酶转化为 UMP。

  • GC11532 structure
    GC11532Lonidamine
    CAS: 50264-69-2
    纯度: >99.00%

    Lonidamine是一种己糖激酶、线粒体丙酮酸载体(在分离的大鼠肝脏线粒体中Ki为2.5μM)和质膜单羧酸转运蛋白抑制剂,同时还抑制线粒体复合物 II。

  • GC11537 structure
    GC11537MK-4827 tosylate
    CAS: 1038915-73-9
    纯度: >99.50%

    An orally bioavailable PARP1/2 inhibitor

  • GC11543 structure
    GC11543Cesium chloride
    CAS: 7647-17-8

    氯化铯是钾通道的阻滞剂。

  • GC11547 structure
    GC11547MI-773 (SAR405838)
    CAS: 1303607-60-4
    纯度: >95.00% / >98.00%

    An inhibitor of MDM2-p53 protein-protein interactions

  • GC11559 structure
    GC11559Anisomycin
    CAS: 22862-76-6
    纯度: >98.50% / >98.00%

    Anisomycin是一种从灰链霉菌中分离出来的抗生素,也是一种JNK激活剂。

  • GC11561 structure
    GC11561NSC 95397
    CAS: 93718-83-3
    纯度: >98.00%

    An irreversible inhibitor of Cdc25 isoforms

  • GC11572 structure
    GC11572Bardoxolone methyl
    CAS: 218600-53-4
    纯度: >98.50%

    Bardoxolone methyl是核因子红细胞2相关因子2(Nrf2)介导的抗氧化和抗炎反应的有效激活剂,也是NF-κB通路的抑制剂。

  • GC11574 structure
    GC11574HPOB
    CAS: 1429651-50-2

    A potent and selective inhibitor of HDAC6

  • GC11589 structure
    GC11589AKT inhibitor VIII
    CAS: 612847-09-3
    纯度: >98.50%

    A potent inhibitor of Akt1 and Akt2

  • GC11625 structure
    GC11625Entinostat (MS-275,SNDX-275)
    CAS: 209783-80-2
    纯度: >99.00% / >98.00%

    Entinostat (MS-275,SNDX-275)是一种强效的、可口服的组蛋白去乙酰化酶(HDACs)抑制剂,对HDAC1和HDAC3的IC₅₀分别为0.368μM和0.501μM,但对HDAC8的抑制作用相对较弱。

  • GC11632 structure
    GC11632Brassinolide
    CAS: 72962-43-7
    纯度: >98.00%

    Brassinolide是一种植物甾醇,最初从油菜( Brassica napus L. )花粉中分离出来,在植物生长、发育和逆境耐受性方面发挥重要作用。